{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:35:43Z","timestamp":1784604943947,"version":"3.55.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.soc.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T08:01:56Z","timestamp":1479974516000},"page":"73-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of the Primary Tumor in Anal Canal Cancers"],"prefix":"10.1016","volume":"26","author":[{"given":"Rob","family":"Glynne-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2006.12.052","article-title":"Predictors and patterns of recurrence after definitive chemoradiation for anal cancer","volume":"68","author":"Das","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.soc.2016.07.003_bib2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2009.09.029","article-title":"Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity modulated radiation treatment planning","volume":"78","author":"Wright","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.soc.2016.07.003_bib3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"10.1016\/j.soc.2016.07.003_bib4","article-title":"The pattern and timing of disease recurrence in squamous cancer of the anus: mature results from the NCRI ACT II trial","volume":"30","author":"Sebag-Montefiore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.soc.2016.07.003_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/BF02553933","article-title":"An evaluation of combined therapy for squamous call carcinoma of the anal canal","volume":"27","author":"Nigro","year":"1984","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.soc.2016.07.003_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid Anal Cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin","volume":"348","author":"UKCCCR Anal Cancer Working Party","year":"1996","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib8","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2016.07.003_bib9","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.soc.2016.07.003_bib10","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.soc.2016.07.003_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib12","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.soc.2016.07.003_bib13","doi-asserted-by":"crossref","first-page":"iii10","DOI":"10.1093\/annonc\/mdu159","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis treatment and follow up","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib14","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: anal carcinoma, version 2, 2016. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed August 12, 2016."},{"key":"10.1016\/j.soc.2016.07.003_bib15","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2016.07.003_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2013.05.037","article-title":"Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort","volume":"108","author":"Bentzen","year":"2013","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.soc.2016.07.003_bib17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumour clonage and repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","article-title":"Loss of local control with prolongation in radiotherapy","volume":"23","author":"Fowler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib20","first-page":"104","article-title":"Cisplatin (P) and 5 fluorouracil (5FU), for the neoadjuvant treatment (Tt) of epidermoid anal canal carcinoma (EACC)","volume":"9","author":"Brunet","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1011107105538","volume":"12","author":"Peiffert","year":"2001","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.soc.2016.07.003_bib22","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1200\/JCO.2008.16.2339","article-title":"Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and leukemia group B (CALGB 9281)","volume":"26","author":"Meropol","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0360-3016(88)90429-4","article-title":"Our experience of conservative treatment of anal canal carcinoma combining external irradiation and interstitial implant: 32 cases treated between 1973 and 1982","volume":"14","author":"Ng Ying Kin","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.soc.2016.07.003_bib24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F","article-title":"Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients","volume":"73","author":"Touboul","year":"1994","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","article-title":"Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C","volume":"21","author":"Cummings","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(05)60945-2","article-title":"Combined radiotherapy and chemotherapy for anal cancer","volume":"349","author":"Northover","year":"1997","journal-title":"The Lancet"},{"key":"10.1016\/j.soc.2016.07.003_bib27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/81.11.850","article-title":"Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group Study No. 8314","volume":"81","author":"Sischy","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.soc.2016.07.003_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.soc.2016.07.003_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF02554777","article-title":"Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease","volume":"30","author":"Flam","year":"1987","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.soc.2016.07.003_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1096-9098(199902)70:2<71::AID-JSO2>3.0.CO;2-Y","article-title":"30\u00a0Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy","volume":"70","author":"Hu","year":"1999","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2007.06.072","article-title":"Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma","volume":"70","author":"Hatfield","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib32","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08","volume":"2","author":"John","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.soc.2016.07.003_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijrobp.2007.12.027","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08","volume":"72","author":"Konski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s003840050137","article-title":"Clinical and manometric effects of combined external beam irradiation and brachytherapy for anal cancer","volume":"13","author":"Broens","year":"1998","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib35","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.ijrobp.2012.03.065","article-title":"Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors","volume":"84","author":"Alsadius","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.radonc.2012.03.002","article-title":"The dose-response of the anal sphincter region\u2013an analysis of data from the MRC RT01 trial","volume":"103","author":"Buettner","year":"2012","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.soc.2016.07.003_bib37","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/annonc\/mdu188","article-title":"Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36Gy elective node irradiation dose in anal cancer","volume":"116","author":"Lepinoy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib39","series-title":"The GECESTROH and book of brachy therapy","first-page":"505","article-title":"Anorectal cancer","author":"Mazeron","year":"2000"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib40","first-page":"218","article-title":"HDR brachytherapy for anal cancer","volume":"5","author":"Niehoff","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5114\/jcb.2015.55118","article-title":"MITHRA \u2013 multiparametric MR\/CT image adapted brachytherapy (MR\/CT-IABT) in anal canal cancer: a feasibility study","volume":"7","author":"Tagliaferri","year":"2015","journal-title":"J\u00a0Contemp Brachytherapy"},{"issue":"Suppl","key":"10.1016\/j.soc.2016.07.003_bib42","article-title":"Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP\/5FU in squamous cell carcinoma of the anus: results of ACT II","volume":"30","author":"Glynne-Jones","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2407-8-8","article-title":"Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients","volume":"15","author":"Cho","year":"2008","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib44","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ijrobp.2010.07.1995","article-title":"\u201cMind the gap\u201d\u2013the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)","volume":"81","author":"Glynne-Jones","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.radonc.2012.03.007","article-title":"Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol","volume":"103","author":"Aggarwal","year":"2012","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib46","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib47","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.ijrobp.2011.12.062","article-title":"Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort","volume":"83","author":"Bentzen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijrobp.2009.08.055","article-title":"Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?","volume":"78","author":"Goh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib49","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib50","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2016.07.003_bib51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clon.2014.08.001","article-title":"Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation","volume":"26","author":"Muirhead","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.soc.2016.07.003_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(02)00377-5","volume":"39","author":"Bosset","year":"2003","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.soc.2016.07.003_bib53","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.ejca.2009.06.020","article-title":"Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)","volume":"45","author":"Matzinger","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib54","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000658-199202000-00010","article-title":"Combined chemoradiation therapy for anal cancer. A report of 56 cases","volume":"215","author":"Doci","year":"1992","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0167-8140(97)00192-8","article-title":"Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients","volume":"46","author":"Gerard","year":"1998","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.11161","article-title":"Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index","volume":"97","author":"Hung","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijrobp.2009.11.057","article-title":"Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results","volume":"79","author":"Olivatto","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.soc.2016.07.003_bib58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0360-3016(96)00146-0","article-title":"Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study","volume":"35","author":"Martenson","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.soc.2016.07.003_bib59","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.ijrobp.2011.02.042","article-title":"Long-term follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)","volume":"81","author":"Chakravarthy","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib60","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ijrobp.2013.09.017","article-title":"Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy","volume":"87","author":"Bazan","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.soc.2016.07.003_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2012.06.006","article-title":"Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin","volume":"104","author":"Sebag-Montefiore","year":"2012","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.soc.2016.07.003_bib62","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2013a multicenter phase II study of chemoradiation using a 5\u00a0day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.soc.2016.07.003_bib63","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.ijrobp.2012.12.008","article-title":"Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study","volume":"85","author":"Deenen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.soc.2016.07.003_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","article-title":"Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal","volume":"47","author":"Oliveira","year":"2016","journal-title":"J\u00a0Gastrointest Cancer"},{"key":"10.1016\/j.soc.2016.07.003_bib65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1748-717X-9-124","article-title":"Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma","volume":"9","author":"Thind","year":"2014","journal-title":"Radiat Oncol"},{"issue":"5s","key":"10.1016\/j.soc.2016.07.003_bib66","article-title":"A\u00a0comparison between 5-fluorouracil\/mitomycin (FM) and capecitabine\/mitomycin (CM) in combination with radiation (RT) for squamous cell carcinoma (SCC) of the anal canal","volume":"32","author":"Wan","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.soc.2016.07.003_bib67","article-title":"A\u00a0pilot study of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy (CT) with paclitaxel, capecitabine and mitomycin C for squamous cell anal carcinoma (SCAC)","volume":"33","author":"Gordeev","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib68","doi-asserted-by":"crossref","first-page":"e92071","DOI":"10.1371\/journal.pone.0092071","article-title":"KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)","volume":"9","author":"Casadei Gardini","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.soc.2016.07.003_bib69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/apm.12306","article-title":"KRAS and BRAF mutations in anal carcinoma","volume":"123","author":"Serup-Hansen","year":"2015","journal-title":"APMIS"},{"issue":"16","key":"10.1016\/j.soc.2016.07.003_bib70","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/cncr.28045","article-title":"Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma","volume":"119","author":"Olivatto","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2016.07.003_bib71","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib72","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib73","doi-asserted-by":"crossref","unstructured":"Garg M, Lee JY, Kachnic LA, et\u00a0al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. J Clin Oncol ASCO Annual Meeting Proceedings. 2012. [abstract: 4030].","DOI":"10.1200\/jco.2012.30.15_suppl.4030"},{"key":"10.1016\/j.soc.2016.07.003_bib74","unstructured":"Garg M, Lee JY, Lisa A, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. J Clin Oncol 34, 2016 (suppl; abstr 3522)."},{"issue":"18","key":"10.1016\/j.soc.2016.07.003_bib75","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","article-title":"Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer","volume":"51","author":"Leon","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.soc.2016.07.003_bib76","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/cncr.28449","article-title":"Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma","volume":"120","author":"Moreno","year":"2014","journal-title":"Cancer"},{"issue":"5s","key":"10.1016\/j.soc.2016.07.003_bib77","article-title":"Phase II trial of panitumumab (P) plus mitomycin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with\u00a0squamous cell carcinoma of the anal canal (SCAC): safety and efficacy profile\u2014VITAL study, GEMCAD 09-02 clinical trial","volume":"32","author":"Feliu","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib78","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/ijc.24215","article-title":"Human papilloma virus type distribution in anal cancer and anal intraepithelial lesions","volume":"124","author":"Hoots","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.soc.2016.07.003_bib79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF02553872","article-title":"Anal cancer and human papilloma viruses","volume":"32","author":"Palmer","year":"1989","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.soc.2016.07.003_bib80","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour infiltrating lymphocytes scores effectively stratify outcomes over and above p16 post chemoradiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.soc.2016.07.003_bib81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2014.11.013","article-title":"Influence of human papillomavirus and p16 on treatment outcome of patients with anal cancer","volume":"113","author":"Koerber","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.soc.2016.07.003_bib82","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.28979","article-title":"Human papilloma virus DNA load and p16INK4a expression predict for local control in patients with anal squamous carcinoma treated with chemoradiotherapy","volume":"136","author":"Rodel","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.soc.2016.07.003_bib83","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10620-009-0812-6","article-title":"Molecular biomarkers correlate with disease free survival in patients with anal cell carcinoma treated with chemoradiation","volume":"55","author":"Ajani","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.soc.2016.07.003_bib84","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1158\/1078-0432.CCR-06-0176","article-title":"Hedgehog: an attribute to tumour regrowth after chemoradiotherapy and a target to improve radiation response","volume":"12","author":"Sims-Mourtada","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320716300369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320716300369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:01:24Z","timestamp":1760961684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320716300369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1055320716300369"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2016.07.003","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of the Primary Tumor in Anal Canal Cancers","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}